185537-68-2

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 56613-80-0 D-2-phenylglycinol 

Downstream Products

• 145058-17-9 (3R,5R)-3,4,5,6-tetrahydro-3-methyl-5-phenyl-2H-1,4-oxazin-2-one 
• 1009605-78-0 (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol 
• 2004679-55-2 (3R,5R)-3-butyl-3-methyl-5-phenylmorpholin-2-one 
• 1160107-56-1 (3R,5R)-3-allyl-3-methyl-5-phenylmorpholin-2-one 
• 1160107-59-4 (3R,5R)-3-methyl-3-(pent-4-enyl)-5-phenylmorpholin-2-one 
• 1160107-57-2 (3R,5R)-3-(but-3-enyl)-3-methyl-5-phenylmorpholin-2-one 
• 1160107-55-0 (3R,5R)-3-methyl-5-phenyl-3-vinylmorpholin-2-one 
• 185537-77-3 3(R)-tert-butyl-3-methyl-5(R)-phenyl-2-morpholinone 

Relevant academic research and scientific papers

PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS

The present disclosure provides methods for preparing (7?)-2-((2-amino-7- fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-l-ol or a salt thereof and related key intermediates.

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES

Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

1,3-β-Glucan synthase inhibitor Triterpenoid antifungal agent

Fungal pathogens are responsible for a large number of mild to severe infections worldwide resulting in 1.6 million deaths. With the rapid emergence of drug resistance, the treatment of fungal infections is rapidly becoming unmanageable. Thus, the discovery and development of novel antifungal drugs is an unmet need of the hour. In this context, ibrexafungerp (SCY-078; SCYNEXIS) is the first orally bioavailable agent that has activity against β-glucan synthase, an essential component of the cell wall. It has broad-spectrum activity against a wide range of Candida sp, including those that are resistant to echinocandins. In addition, ibrexafungerp exhibits broad-spectrum fungicidal activity including against multidrug-resistant strains, possesses high tissue penetration and exhibits flexible dosing options including via oral and intravenous routes. The U.S. Food and Drug Administration has granted both qualified infectious disease product and fast track designations for the oral formulation of ibrexafungerp for the treatment and prevention of recurrent vulvovaginal candidiasis.

TOLL LIKE RECEPTOR MODULATOR COMPOUNDS

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.

TOLL LIKE RECEPTOR MODULATOR COMPOUNDS

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

An efficient entry to optically active anti- and syn-β-amino-α- trifluoromethyl alcohols

The reaction of chiral 5,6-dihydro-2H-1,4-oxazin-2-ones with TMSCF 3 in the presence of a suitable activator leads to trifluoromethyl lactols, which can be selectively reduced to anti-β-amino-α- trifluoromethyl alcohols. The corresponding syn d